Drug intelligence / Profile preview

ANTG Eve

Development stage: Unknown
Lead developer: Australian Natural Therapeutics Group
Administration: Oral

Overview

ANTG Eve is a CBD-dominant medicinal cannabis oral oil extract developed by the Australian Natural Therapeutics Group (ANTG). It is a plant-based extract primarily composed of cannabidiol (CBD) with negligible levels of THC. The drug is currently in Phase 2 clinical development for the treatment of mild cognitive impairment and early-stage Alzheimer's disease, specifically within the CANCOG trial initiated in 2023. Additionally, ANTG Eve is being investigated in preclinical studies for its potential therapeutic application in Acute Myeloid Leukemia (AML), where it has demonstrated activity in animal and xenograft models.

Brand names: ANTG EveEve
Other names: CBD-dominant oral oilCBD-dominant oral oil extract

Targets

CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on ANTG Eve.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANTG Eve.

Explore the full profile